Business Context and Reporting Period
Company: Fresenius Medical Care AG & Co. KGaA
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Three months ended March 31, 2006 (Unaudited)
Key Event: On March 31, 2006, the Company completed the acquisition of Renal Care Group, Inc. (RCG) for approximately $3.94 billion. The Company also transformed its legal form from a stock corporation to a partnership limited by shares (KGaA) in February 2006, converting a significant portion of preference shares into ordinary shares.
Key Financial Metrics
| Metric | Q1 2006 | Q1 2005 |
|---|---|---|
| Net Revenue | $1,746.9 million | $1,609.0 million |
| Gross Profit | $578.3 million | $508.7 million |
| Operating Income | $243.8 million | $219.9 million |
| Net Income | $116.0 million | $107.5 million |
| Diluted EPS (Ordinary) | $1.18 | $1.10 |
| Cash from Operations | $161.7 million | $138.5 million |
| Cash and Equivalents (End of Period) | $364.4 million | $50.8 million |
| Total Debt (Short + Long Term) | $4,670.3 million | $984.5 million |
Note: Debt figures include short-term borrowings, current portion of long-term debt, and long-term debt. The significant increase in debt is primarily due to financing the RCG acquisition.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 9% year-over-year, driven by a 9% increase in Dialysis Care revenue and a 6% increase in Dialysis Products revenue. Growth was fueled by increased treatment volumes (6% increase) and higher revenue per treatment.
- Profitability: Operating income margin improved from 13.7% to 14.0%. Gross profit margin increased from 31.6% to 33.1%.
- Acquisition Impact: The RCG acquisition closed on the last day of the quarter. While RCG's operating results are not included in Q1 2006, the transaction significantly altered the balance sheet, increasing total assets by over $5 billion and goodwill by approximately $3.46 billion.
- Interest Expense: Interest expense rose 37% to $61.0 million, largely due to a $14.6 million write-off of unamortized fees from the previous credit agreement replaced to finance the RCG deal.
- Legal Form Transformation: The conversion of preference shares to ordinary shares resulted in a cash inflow of $308.7 million from conversion premiums.
Guidance, Outlook, and Risks
Outlook and Guidance
- 2006 Net Income: Management expects 2006 net income (excluding one-time costs related to the RCG acquisition, legal form transformation, and accounting changes) to be 10-15% higher than the adjusted 2005 net income of $472 million.
- RCG Integration: The RCG acquisition is expected to be earnings neutral to slightly accretive in 2006 and accretive from 2007 onward.
- Divestitures: To satisfy FTC requirements, the Company divested 105 dialysis centers. 96 were sold in April 2006, with 9 more expected to close in Q2 2006, generating approximately $512 million in cash.
- Capital Expenditures: Planned for 2006 in the range of $450 million (including acquisitions).
Risks and Contingencies
- Government Investigations: The Company and RCG are cooperating with U.S. Department of Justice investigations regarding clinical quality, physician relations, and billing practices (including PTH testing and vitamin D therapies). Adverse outcomes could materially affect operations.
- W.R. Grace Litigation: The Company has a $115 million payment obligation to the W.R. Grace bankruptcy estate pending plan confirmation. There are also ongoing disputes regarding indemnification for pre-merger tax liabilities.
- Patent Litigation: A patent infringement suit with Baxter International regarding hemodialysis machine technology is scheduled for trial in June 2006.
- Reimbursement Risk: Approximately 36% of consolidated revenue comes from U.S. federal programs (Medicare/Medicaid). Changes in reimbursement rates or drug utilization policies (e.g., EPO monitoring) pose significant risks.
Investor Verification Checklist
- RCG Integration: Verify the timeline for RCG's inclusion in consolidated results (starting April 1, 2006) and the impact of the mandated divestitures on future revenue.
- Debt Covenants: Confirm compliance with the new $4.6 billion credit facility covenants, specifically the consolidated leverage ratio and fixed charge coverage ratio.
- Legal Settlements: Monitor the status of the W.R. Grace bankruptcy plan confirmation and the outcome of the Baxter patent trial.
- Regulatory Investigations: Track the progress of DOJ investigations into billing and physician relations for potential fines or operational restrictions.
- Accounting Changes: Review the impact of FAS 123(R) adoption on future stock-based compensation expenses.